Search for: "CIPLA"
Results 121 - 140
of 202
Sort by Relevance
|
Sort by Date
1 Sep 2009, 3:53 am
One hopes that unlike the judges in Roche vs Cipla, the Supremes will not throw away this brilliant opportunity to clarify the scope and ambit of section 3(d), a section that appears to be severely creased. [read post]
22 Jul 2009, 6:05 am
Mylan Inc (Global IP Watch) Lexapro (Escitalopram) – US: Forest and Sun settle Lexapro patent suit (Patent Docs) Lovenox (Enoxaparin) – US: Judge denies attorney fees to Sandoz in patent infringement dispute with Sanofi-Aventis (Patent Docs) Norflox-TZ (Norfloxacin) and Aerocort (Salbutamol) – India: Cipla attracts NPPA’s attention again – alleged overpricing of Salbutamol and Norfloxacin (Spicy IP) Ovide (Malathion) – US: Taro… [read post]
11 Jul 2009, 7:45 am
., Cipla Ltd., Ranbaxy Ltd. and Hetero Drugs Ltd. and subsequently got rejected by the Chennai Patent Office on January 25, 2006. [read post]
1 Jul 2009, 7:14 am
OHIM decision in Laboratorios Andrómaco, S.A. v OTC Pharma International B V (Class 46) India: Valgancyclovir hearings and the need for more transparency: Roche v Cipla (Spicy IP) Japan approves first follow-on biologic (Patent Docs) UK: Journal of Intellectual Property Law & Practice note on ‘Paediatric extensions: the requirement of a compliance statement’ on UK IPO decision in Merck and Co, Inc (The SPC Blog) US: Sen Nelson introduces s 1315 bill to… [read post]
12 May 2009, 11:49 pm
Unfortunately, the divisional bench was so inclined by Cipla’s arguments that the Court penalized Roche to pay Cipla Rs. 5 Lakhs (approx. [read post]
8 May 2009, 8:00 am
(Property intangible) US: Supreme Court rules 9-0 that CAFC has jurisdiction to review case remanded by district court to state court: Carlsbad Technology Inc v HIF Bio, Inc et al (Managing Intellectual Property) (Patently-O) US: Anticipation by a laundry list of prophetic DNA sequences: In re Gleave (Holman's Biotech IP Blog) US: Reverse payment settlements and biotechnology (Holman's Biotech IP Blog) US: Biogen seeks review and correction of patent term adjustment calculation in respect… [read post]
1 May 2009, 9:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Tarceva (Erlotinib) – India: Delhi High Court Appellate Bench holds in favour of Cipla against Roche in Tarceva patent litigation; Roche fined for ‘material suppression’ (Spicy IP) (PatLit) (Patent Circle) (Spicy IP) (Patent Circle) (Patent Circle) (GenericsWeb) Lovenox (Enoxaparin) – US: Supreme… [read post]
30 Apr 2009, 1:50 pm
After the single judge rejected Roche’s appeal for temporary injunction against Cipla, Roche appealed the single judge decision. [read post]
28 Apr 2009, 10:04 am
In December 2008, the Delhi Patent Office rejected OSI Pharmaceuticals patent application number IN/PCT/2002/507/DEL for polymorph B form of erlotinib hydrochloride in a pre-grant opposition proceeding filed by Cipla. [read post]
28 Apr 2009, 10:04 am
IN/PCT/2002/507/DEL for polymorph B form of erlotinib hydrochloride in a pre-grant opposition proceeding filed by Cipla. [read post]
27 Apr 2009, 1:47 am
[Download] the Delhi High Court decision rejecting Roche appeal against the Delhi HC judgment dated March 19, 2008 declining their appeal for grant of an interim injunction to restrain the Cipla from manufacturing, offering for sale, selling and exporting the drug Erlotinib. [read post]
17 Apr 2009, 12:00 am
Ltd. sues 11 generics companies over Levaquin patents (Law 360) Lexapro (Escitalopram) – Netherlands District court invalidates Lundbeck’s patent EP ‘066 (IPKat) Lexapro (Escitalopram) - Baldwin’s rules explained (The SPC Blog) Lexapro (Escitalopram) – federal district Judge agrees to determine whether Forest Laboratories destroyed key documents (Law 360) Pegasys (PEG interferon alfa 2a) – Roche wins post grant opposition against Wockhardt… [read post]
15 Apr 2009, 4:05 am
The Delhi Patent Office decided the pre-grant opposition in favor of Cipla Ltd. after it found that the applicant (Gilead) failed to provide any supportive evidence in the specification by means of comparative data or by way of examples which would have supported the inventive merit of Oseltamivir. [read post]
3 Apr 2009, 8:31 am
Now Hetero launches its generic Dasatinib in August 2011 soon after BMS-Cipla case and sued by BMS for patent infringement. [read post]
4 Mar 2009, 11:00 pm
(Spicy IP) Kenya enacts Biosafety Act 2/2009 regulating activities in GMOs, establishing National Biosafety Authority (Afro-IP) US: BIO meets the press: economic health of the biotech industry; follow-on biologics; patent reform (Patent Docs) (Patent Docs) (Intellectual Property Watch) US: Obama touts generic biologics to lower drug costs (Law360) US: Genentech announces victory in Cabilly re-examination (Patent Docs) US: Federal judge rejects Scruggs family’s bid to reconsider summary… [read post]
27 Feb 2009, 5:00 am
(Patent Docs) Lexapro (Escitalopram) – US: Supreme Court refuses to hear appeal from Forest Lab’s allowing Caraco to continue bid to invalidate Lexapro patent despite Forest’s earlier covenant to sue (Law360) (Hal Wegner) Lotrel (Amlodipine) – US: Par and Novartis settle Lotrel lawsuit (Patent Docs) (GenericsWeb) Lovenox (Enoxaparin) – US: Amphastar antitrust claims nixed in Lovenox suit against Sanofi-Aventis (Law360) Opana (Oxymorphone)… [read post]
26 Feb 2009, 2:37 am
" Last year we hinted that Cipla may possibly target patented drugs, mostly tyrosine kinase inhibitors. [read post]
19 Feb 2009, 12:13 am
Why Cipla's counsel argued the Court to disregard the IPO finding in favor of Roche? [read post]
18 Feb 2009, 12:21 pm
However, on reviewing Erlotinib pre-grant opposition judgment we found Cipla's argument contradicting and fallacious. [read post]
16 Feb 2009, 9:00 pm
In this week's call, regular panelists Jeremy Phillips, Shamnad Basheer and Duncan Bucknell are joined by special guests Nick Redfearn and Don Zuhn to discuss: Fallout from the World Trade Organisation dispute between China and the United States; Dr Reddy's, CIPLA, India, Brazil and the EU and the emerging controversy over seized pharmaceutical goods; TRIPS compliance and too much protection within a country; The infringement approach to goods… [read post]
